Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
News Menu

News

Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks

PR Newswire - Press Release

All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here

SYNB2081 is the second clinical drug candidate developed through the partnership between Ginkgo and Synlogic

CAMBRIDGE, Mass. and BOSTON, Aug. 11, 2022 /PRNewswire/ -- Synlogic, Inc. (Nasdaq:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced a new drug candidate for the treatment of gout developed in partnership with Ginkgo Bioworks (NYSE:DNA), the leading horizontal platform for cell programming. The new candidate, SYNB2081, is a Synthetic Biotic and is the second product to advance to clinical development through a research collaboration between Synlogic and Ginkgo, following the investigational new drug candidate SYNB1353 for the potential treatment of homocystinuria (HCU).

Read more at prnewswire.com

Related Symbols

Symbol Last Chg %Chg
DNA 10.10 +1.78 +21.39%
Ginkgo Bioworks Hldgs Inc
SYBX 0.5950 -0.0350 -5.56%
Synlogic Inc

Most Popular News

Buy enter button by Ardasavasciogullari via iStock 1
These 3 Dividend Stocks Combine Income, Momentum, and Upside
Wall street sign in New York with New York Stock Exchange background by Stuart Monk via Shutterstock 2
Stock Index Futures Climb After Tech Rout, Amazon Slips on CapEx Blowout
OPTIONS TRADING open book on table by One Photo via Shutterstock 3
Unusual Options Activity Alert: 3 Stocks Setting Up for Major Profit Potential
A Palantir sign displayed on an office building by Poetra_RH via Shutterstock 4
Wall Street Is Cozying Up to Palantir Stock After Q4. Does That Make PLTR a Buy Here?
Conoco Phillips gas station- by helen89 via iStock 5
ConocoPhillips Stock Still Looks Cheap - What's The Best Play Here?
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot